Taylor Leigh Garza

Dr. Taylor Leigh Garza

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2026 in Cancers
Verified
Journal Article
Open access
PDF file
TGTaylor Leigh Garza
Taylor Leigh Garza
Jae Hwan ChoiJae Hwan Choi
Jae Hwan Choi
MMMichelle McGee
Michelle McGee
EBEdmond W Box
Edmond W Box
TNTimothy Nywening
Timothy Nywening
RJRichard Jacobson
Richard Jacobson
Roughly 100,000 new cases of melanoma are diagnosed yearly in the United States, the majority of which are early-stage disease with excellent prognosis. However, a subset of patients harbors clinically occult aggressive biology that can go undetected on standard clinicopathologic analyses. Gene expression profiling (GEP) assays have emerged as molecular adjuncts to risk stratification, aiming to improve sentinel lymph node biopsy (SLNB) decision-making and surveillance planning. Two commercial tests are widely available: the 31-gene expression profile (31-GEP, DecisionDx-Melanoma, Castle Biosciences) and the clinicopathologic gene expression profile (CP-GEP, Merlin, SkylineDx). This review summarizes the current evidence for each assay regarding their performance and utility, with a focus on potentially actionable use cases, limitations, and the practical context in which these tools are most valuable.